The binding of sERGIC-53-SA-MCFD2 to DMJ-treated cells is inhibited by mannose and high mannose-type glycans. (A) sERGIC-53-SA-MCFD2 (20 μg/mL) and the indicated concentrations of various monosaccharides were mixed with DMJ-treated HeLaS3 cells. The binding of sERGIC-53-SA in the presence of each monosaccharide is shown relative to the absence of monosaccharide, adjusted to 100%. The data shown are means of 3 independent experiments. Man indicates mannose; Glc, glucose; Fuc, fucose; Gal, galactose. The inhibition by N-acetylgalactosamine and N-acetylglucosamine is similar to the inhibition by galactose and glucose, respectively (data not shown). (B) Structures of high mannose-type glycans used in inhibition assay are shown. The A arm of the glycan is underlined. Man, mannose (●); Glc, glucose (▵); GlcNAc, N-acetylglucosamine. (C) sERGIC-53-SA-MCFD2 (10 μg/mL) and various high mannose-type glycans (15 mg/mL) were added to DMJ-treated HeLaS3 cells. The binding of sERGIC-53-SA-MCFD2 in the presence of each oligosaccharide is shown relative to that in the absence of oligosaccharide (none) adjusted to 100%.